Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06735820

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST (MEKMDM2)

Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors

Sponsor: AeRang Kim

Conditions Atypical Neurofibroma Malignant Peripheral Nerve Sheath Tumor (MPNST) Neurofibromatosis 1 (NF1)

Interventions APG-115 Selumetinib

Updated 3 times since 2025 Last updated: Jul 1, 2025 Started: Oct 1, 2025 Primary completion: Oct 1, 2027 Completion: Oct 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Atypical Neurofibroma and Malignant Peripheral Nerve Sheath Tumor (MPNST), this trial is actively recruiting participants. The trial is conducted by AeRang Kim and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jan 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AeRang Kim
Children's National Research Institute

Data source: Children's National Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Washington D.C., United States